JPH05502879A - キノロンカルボン酸―金属イオン―酸錯体 - Google Patents
キノロンカルボン酸―金属イオン―酸錯体Info
- Publication number
- JPH05502879A JPH05502879A JP91502902A JP50290291A JPH05502879A JP H05502879 A JPH05502879 A JP H05502879A JP 91502902 A JP91502902 A JP 91502902A JP 50290291 A JP50290291 A JP 50290291A JP H05502879 A JPH05502879 A JP H05502879A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- methyl
- oxo
- piperazinyl
- metal ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 title claims abstract description 34
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 16
- 239000002184 metal Substances 0.000 title claims abstract description 16
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 37
- -1 quinolone carboxylic acids Chemical class 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 67
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 18
- 229910021645 metal ion Inorganic materials 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000011777 magnesium Substances 0.000 claims description 9
- QKDHBVNJCZBTMR-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Chemical compound C1CNC(C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-UHFFFAOYSA-N 0.000 claims description 8
- 229960001231 choline Drugs 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 7
- 229940097043 glucuronic acid Drugs 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 claims 4
- 239000005973 Carvone Substances 0.000 claims 2
- 239000012670 alkaline solution Substances 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 abstract description 8
- 230000007794 irritation Effects 0.000 abstract description 7
- 238000007911 parenteral administration Methods 0.000 abstract description 7
- 210000003462 vein Anatomy 0.000 abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 37
- 229960004576 temafloxacin Drugs 0.000 description 28
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 229940097042 glucuronate Drugs 0.000 description 8
- 208000035143 Bacterial infection Diseases 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 238000002845 discoloration Methods 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002510 mandelic acid Drugs 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- VHCQVGQULWFQTM-UHFFFAOYSA-N Rubone Natural products COC1=CC(OC)=CC(O)=C1C(=O)C=CC1=CC(OC)=C(OC)C=C1OC VHCQVGQULWFQTM-UHFFFAOYSA-N 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- NOCJXYPHIIZEHN-UHFFFAOYSA-N difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 description 2
- 229950001733 difloxacin Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940045996 isethionic acid Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940099563 lactobionic acid Drugs 0.000 description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- DDVJEYDLTXRYAJ-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydron;chloride Chemical compound Cl.C1CNC(C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F DDVJEYDLTXRYAJ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 1
- XBHBWNFJWIASRO-UHFFFAOYSA-N 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1 XBHBWNFJWIASRO-UHFFFAOYSA-N 0.000 description 1
- HRTAGUYKZCRJSK-UHFFFAOYSA-N 7-(3-methylpiperazin-1-yl)-4-oxo-3h-quinoline-3-carboxylic acid Chemical compound C1CNC(C)CN1C1=CC=C(C(=O)C(C=N2)C(O)=O)C2=C1 HRTAGUYKZCRJSK-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- CCNMTCHDGVNKBI-UHFFFAOYSA-K aluminum;methanesulfonate Chemical compound [Al+3].CS([O-])(=O)=O.CS([O-])(=O)=O.CS([O-])(=O)=O CCNMTCHDGVNKBI-UHFFFAOYSA-K 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229950007734 sarafloxacin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960004840 temafloxacin hydrochloride Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/06—Aluminium compounds
- C07F5/069—Aluminium compounds without C-aluminium linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (9)
- 1.約4から約10のpHを有する、生理的に許容可能なキャリヤに溶解したキ ノロンカルボン酸−金属イオン−酸錯体を含む医薬組成物。
- 2.金属イオンがマグネシウムまたはカルシウムであることを特徴とする請求項 1に記載の組成物。
- 3.キノロンカルボン酸−金属イオン−酸錯体が1−(2,4−ジフルオロフェ ニル)−6−フルオロ−1,4−ジヒドロ−7−(3−メチル−1−ピペラジニ ル)−4−オキソ−3−キノリンカルボン酸−Mg−HCl;1−(2,4−ジ フルオロフェニル)−6−フルオロ−1,4−ジヒドロ−7−(3−メチル−1 −ピペラジニル)−4−オキソ−3−キノリンカルボン酸−Mg−メタンスルホ ネート;1−(2,4−ジフルオロフェニル)−6−フルオロ−1,4−ジヒド ロ−7−(3−メチル−1−ピペラジニル)−4−オキソ−3−キノリンカルボ ン酸−Mg−イセチオネート;1−(2,4−ジフルオロフェニル)−6−フル オロ−1,4−ジヒドロ−7−(3−メチル−1−ピペラジニル)−4−オキソ −3−キノリンカルボン酸−Ca−HCl;1−(2,4−ジフルオロフェニル )−6−フルオロ−1,4−ジヒドロ−7−(3−メチル−1−ピペラジニル) −4−オキソ−3−キノリンカルボン酸−Al−メタンスルホネート;1−(2 ,4−ジフルオロフェニル)−6−フルオロ−1,4−ジヒドロ−7−(3−メ チル−1−ピペラジニル)−4−オキソ−3−キノリンカルボン酸−Mg−グル クロネート;1−(2,4−ジフルオロフェニル)−6−フルオロ−1,4−ジ ヒドロ−7−(3−メチル−1−ピペラジニル)−4−オキソ−3−キノリンカ ルボン酸−Mg−ラクテート;1−(2,4−ジフルオロフェニル)−6−フル オロ−1,4−ジヒドロ−7−(3−メチル−1−ピペラジニル)−4−オキソ −3−キノリンカルボン酸−Mg−マンデレート;1−(2,4−ジフルオロフ ェニル)−6−フルオロ−1,4−ジヒドロ−7−(3−メチル−1−ピペラジ ニル)−4−オキソ−3−キノリンカルボン酸−Mg−システエート;及び1− (2,4−ジフルオロフェニル)−6−フルオロ−1,4−ジヒドロ−7−(3 −メチル−1−ピペラジニル)−4−オキソ−3−キノリンカルボン酸HCl− Mg−コリンの中から選択されることを特徴とする請求項1に記載の組成物。
- 4.キノロンカルボン酸−金属イオン−酸錯体のキノロンカルボン酸が1−(2 ,4−ジフルオロフェニル)−6−フルオロ−1,4−ジヒドロ−7−(3−メ チル−1−ピペラジニル)−4−オキソ−3−キノリンカルボン酸であり、金属 イオンはマグネシウムであり、酸はグルクロン酸であることを特徴とする請求項 1に記載の組成物。
- 5.請求項1に記載の組成物を調製する方法であって、(a)キノロンカルボン 酸の酸性塩を金属イオン塩の溶液中に懸濁させて、キノロンカルボン酸−金属イ オン−酸錯体の懸濁液を製造し、 (b)この懸濁液のpHを、前記錯体を溶解させるアルカリ性溶液で調整して約 4から約10とすることを含む組成物調製方法。
- 6.請求項1に記載の組成物を調製する方法であって、(a)キノロンカルボン 酸を金属イオン塩の溶液中に懸濁させること、及び (b)pHが約4から約10であるキノロンカルボン酸−金属イオン−酸錯体溶 液を製造すること を含む組成物調製方法。
- 7.錯体溶液の製造を、 (a)前記懸濁によって得られた懸濁液に酸を添加して該懸濁液のpHを低下さ せるステップ、及び(b)約4から約10のpHを有するキノロンカルボン酸− 金属イオン−酸錯体溶液の生成に十分な量の塩基を添加するステップ によって実施することを特徴とする請求項6に記載の方法。
- 8.錯体溶液の製造を、 (a)前記懸濁によって得られた懸濁液に塩基を添加して該懸濁液のpHを上昇 させるステップ、及び(b)約4から約10のpHを有するキノロンカルボン酸 −金属イオン−酸錯体溶液の生成に十分な量の酸を添加するステップ によって実施することを特徴とする請求項6に記載の方法。
- 9.キノロンカルボン酸が1−(2,4−ジフルオロフェニル)−6−フルオロ −1,4−ジヒドロ−7−(3−メチル−1−ピペラジニル)−4−オキソ−3 −キノリンカルボン酸であり、金属イオンはマグネシウムであることを特徴とす る請求項6に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45892789A | 1989-12-29 | 1989-12-29 | |
US458,927 | 1989-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05502879A true JPH05502879A (ja) | 1993-05-20 |
JP3153549B2 JP3153549B2 (ja) | 2001-04-09 |
Family
ID=23822659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50290291A Expired - Lifetime JP3153549B2 (ja) | 1989-12-29 | 1990-12-20 | キノロンカルボン酸―金属イオン―酸錯体 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5334589A (ja) |
EP (1) | EP0507851B1 (ja) |
JP (1) | JP3153549B2 (ja) |
AT (1) | ATE150973T1 (ja) |
AU (1) | AU647772B2 (ja) |
CA (1) | CA2072366C (ja) |
DE (1) | DE69030387T2 (ja) |
DK (1) | DK0507851T3 (ja) |
ES (1) | ES2102393T3 (ja) |
GR (1) | GR3023542T3 (ja) |
IE (1) | IE904725A1 (ja) |
IL (1) | IL96776A (ja) |
PT (1) | PT96400B (ja) |
WO (1) | WO1991009525A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004028A1 (ja) * | 2004-07-02 | 2006-01-12 | Daiichi Pharmaceutical Co., Ltd. | キノロン含有医薬組成物 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9118183D0 (en) * | 1991-08-23 | 1991-10-09 | Solanki Kishor K | Imaging of infections |
US5290794A (en) * | 1992-10-27 | 1994-03-01 | Warner Lambert Co. | Soluble calcium lactate antibacterial complexes as non-irritating parenteral forms |
US6024979A (en) * | 1995-06-06 | 2000-02-15 | Solvay Animal Health, Inc. | Oral veterinary composition containing a fluoroquinolone antibacterial agent possessing superior absorption properties and an extended duration of therapeutic antimicrobial blood levels, and a method of treating a microbial infection in a ruminant |
SK284412B6 (sk) * | 1995-12-21 | 2005-03-04 | Pfizer Inc. | Vodný farmaceutický roztok vhodný na injekčné podávanie hostiteľovi |
ID21415A (id) | 1997-12-05 | 1999-06-10 | Upjohn Co | Senyawa-senyawa antibiotik magnesium quinolon |
DE19937116A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
DE19937115A1 (de) | 1999-08-06 | 2001-02-08 | Bayer Ag | Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon |
DE10018781A1 (de) * | 2000-04-15 | 2001-10-25 | Fresenius Kabi De Gmbh | Infusionslösungen des Ciprofloxacins mit verbesserter Lagerfähigkeit |
US8524734B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
US20070197548A1 (en) * | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V S | Fluoroquinolone compositions |
DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
LT2344129T (lt) | 2008-10-07 | 2018-05-10 | Horizon Orphan Llc | Aerozolinės fluorchinolono kompozicijos, skirtos farmakokinetikų pagerinimui |
JP2012505222A (ja) | 2008-10-07 | 2012-03-01 | エムペックス・ファーマシューティカルズ・インコーポレーテッド | 肺炎症を低減するためのレボフロキサシンの吸入 |
BR112012004692B8 (pt) | 2009-09-04 | 2021-05-25 | Mpex Pharmaceuticals Inc | solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano |
US10406149B2 (en) | 2015-06-02 | 2019-09-10 | Kyorin Pharmaceutical Co., Ltd. | Aqueous liquid formulation |
CA2987879A1 (en) | 2015-06-02 | 2016-12-08 | Kyorin Pharmaceutical Co., Ltd. | Aqueous drug |
JP6675396B2 (ja) | 2015-06-02 | 2020-04-01 | 杏林製薬株式会社 | 水性液剤 |
CN105524060B (zh) * | 2016-03-10 | 2017-03-22 | 青岛云天生物技术有限公司 | 一种制备盐酸莫西沙星的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4730000A (en) * | 1984-04-09 | 1988-03-08 | Abbott Laboratories | Quinoline antibacterial compounds |
NZ208470A (en) * | 1983-07-18 | 1988-06-30 | Abbott Lab | 6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid derivatives and antibacterial compositions containing such |
DE3333719A1 (de) * | 1983-09-17 | 1985-04-04 | Bayer Ag | Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren |
DE3713672A1 (de) * | 1987-04-24 | 1988-11-17 | Bayer Ag | Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren |
JP2832535B2 (ja) * | 1989-04-04 | 1998-12-09 | 富山化学工業株式会社 | キノロンカルボン酸またはその塩の可溶化法 |
FR2665635A1 (fr) * | 1990-08-10 | 1992-02-14 | Merck Sharp & Dohme | Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation. |
-
1990
- 1990-12-20 AU AU71531/91A patent/AU647772B2/en not_active Expired
- 1990-12-20 JP JP50290291A patent/JP3153549B2/ja not_active Expired - Lifetime
- 1990-12-20 EP EP91902370A patent/EP0507851B1/en not_active Expired - Lifetime
- 1990-12-20 DE DE69030387T patent/DE69030387T2/de not_active Expired - Lifetime
- 1990-12-20 DK DK91902370.5T patent/DK0507851T3/da active
- 1990-12-20 CA CA002072366A patent/CA2072366C/en not_active Expired - Lifetime
- 1990-12-20 ES ES91902370T patent/ES2102393T3/es not_active Expired - Lifetime
- 1990-12-20 WO PCT/US1990/007584 patent/WO1991009525A1/en active IP Right Grant
- 1990-12-20 AT AT91902370T patent/ATE150973T1/de not_active IP Right Cessation
- 1990-12-24 IL IL9677690A patent/IL96776A/xx not_active IP Right Cessation
- 1990-12-28 IE IE472590A patent/IE904725A1/en not_active IP Right Cessation
- 1990-12-28 PT PT96400A patent/PT96400B/pt not_active IP Right Cessation
-
1992
- 1992-06-25 US US07/867,200 patent/US5334589A/en not_active Expired - Lifetime
-
1997
- 1997-05-23 GR GR970401192T patent/GR3023542T3/el unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004028A1 (ja) * | 2004-07-02 | 2006-01-12 | Daiichi Pharmaceutical Co., Ltd. | キノロン含有医薬組成物 |
JPWO2006004028A1 (ja) * | 2004-07-02 | 2008-04-24 | 第一製薬株式会社 | キノロン含有医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
AU647772B2 (en) | 1994-03-31 |
AU7153191A (en) | 1991-07-24 |
DE69030387T2 (de) | 1997-10-23 |
ATE150973T1 (de) | 1997-04-15 |
PT96400A (pt) | 1991-10-15 |
DK0507851T3 (da) | 1997-08-25 |
IL96776A (en) | 1997-02-18 |
GR3023542T3 (en) | 1997-08-29 |
CA2072366C (en) | 2002-08-20 |
IL96776A0 (en) | 1991-09-16 |
CA2072366A1 (en) | 1991-06-30 |
PT96400B (pt) | 1998-06-30 |
WO1991009525A1 (en) | 1991-07-11 |
EP0507851A1 (en) | 1992-10-14 |
IE904725A1 (en) | 1991-07-17 |
US5334589A (en) | 1994-08-02 |
ES2102393T3 (es) | 1997-08-01 |
EP0507851A4 (en) | 1993-03-17 |
DE69030387D1 (de) | 1997-05-07 |
EP0507851B1 (en) | 1997-04-02 |
JP3153549B2 (ja) | 2001-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05502879A (ja) | キノロンカルボン酸―金属イオン―酸錯体 | |
RU2260429C9 (ru) | Составы моксифлоксацина, содержащие поваренную соль | |
JPH09301858A (ja) | グルコン酸クロルヘキシジン安定化水性薬剤 | |
JPH0559893B2 (ja) | ||
JPH11501331A (ja) | 注射用キノロン製剤 | |
JP2003513046A (ja) | フルオロキノロン抗生薬およびキサンタンガムを含有する薬学的組成物 | |
JPH0680012B2 (ja) | 二価金属イオンと複合体を形成した4−キノロン誘導体を含有する組成物 | |
EP0604570B1 (en) | Compositions containing quinolone antibiotics and sulfonate of polystyrol | |
JP2003509351A (ja) | レボシメンダンの医薬溶液 | |
US6288080B1 (en) | Magnesium quinolone antibiotics | |
KR19980071022A (ko) | 피리돈카복실산의 가용화 방법, 가용화제 및 가용화된피리돈카복실산을 함유한 수성 액제 | |
US5276044A (en) | Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions | |
JPH03118321A (ja) | 透明且つ安定なクロモリン剤 | |
JPH0637388B2 (ja) | 水性液剤 | |
JPS63174930A (ja) | キノロンカルボン酸の水性組成物 | |
US5084276A (en) | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation | |
JP3424038B2 (ja) | 合成抗菌剤水性組成物 | |
JP4578576B2 (ja) | ガチフロキサシン含有水性液剤 | |
US5290794A (en) | Soluble calcium lactate antibacterial complexes as non-irritating parenteral forms | |
KR0159540B1 (ko) | 퀴놀론-카복실산의 염 및 그 함유조성물 | |
JPS635091A (ja) | 着色防止方法 | |
JPH0459726A (ja) | ピリドンカルボン酸の可溶化方法 | |
JPS61260020A (ja) | 眼部局所投与剤 | |
JP2002544164A (ja) | 5−(2−クロロエチル)−4−メチルチアゾールエジシレート(クロメチアゾールエジシレート)の非経口処方物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080126 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090126 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090126 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110126 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term |